154 CHAPTER 7 20 Rech J, Ostergaard M, Tascilar K, Hagen M, Mendez L V, Kleyer A, Kroenke G, Simon D, Schoenau V, Hueber A, Kleinert S, Baraliakos X, Fleck M, Rubbert-Roth A, Behrens F, Kofler D, Feuchtenberger M, Zaenker M, Voll R, et al. 2021; Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients. Arthritis Rheumatol. 73:939–41. 21 Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool MJF, van Tubergen A, Janssen M, de Hair M, Hansson M, de Vries N, Zwinderman AH, Tak PP. 2019; Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 78(2):179–85. 22 Deane K, Striebich C, Feser M, Demoruelle K, Moss L, Bemis E, Frazer-Abel A, Fleischer C, Sparks J, Solow E, James J, Guthridge J, Davis J, Graf J, Kay J, Danila M, Bridges SJ, Forbess L, O’Dell J, et al. 2022; Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial [abstract]. Arthritis Rheumatol. 74(suppl 9). 23 Cope A, Jasenecova M, Vasconcelos J, Filer A, Raza K, Qureshi S, D’agostino MA, Mcinnes I, Isaacs J, Pratt A, Fisher B, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, Huizinga T, Schaardenburg D Van, Murphy C, et al. 2023; Abatacept in individuals at risk of developing rheumatoid arthritis: results from the arthritis prevention in the pre-clinical phase of RA with abatacept (APIPPRA) trial [abstract OP0130]. Ann Rheum Dis. 82(Suppl 1):86 LP – 86. 24 2022. Trial registration: Phase II proof of concept study of baricitinib in individuals who are considered at risk of developing inflammatory arthritis: ExIST [Internet]. 25 Boheemen L van, Wee MM ter, Seppen B, Schaardenburg D van. 2021; How to enhance recruitment of individuals at risk of rheumatoid arthritis into trials aimed at prevention: understanding the barriers and facilitators. RMD Open. 7(1):e001592. 26 Simons G, Veldwijk J, DiSantostefano RL, Englbrecht M, Radawski C, Bywall KS, Valor Méndez L, Hauber B, Raza K, Falahee M. 2023; Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania. Rheumatology. 62(2):596–605. 27 Finckh A, Escher M, Liang MH, Bansback N. 2016; Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences. Curr Rheumatol Rep. 18(8):51. 28 van Boheemen L, Turk S, Beers-Tas M V, Bos W, Marsman D, Griep EN, Starmans-Kool M, Popa CD, van Sijl A, Boers M, Nurmohamed MT, van Schaardenburg D. 2021; Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open. 7(1). 29 Stack RJ, Nightingale P, Jinks C, Shaw K, Herron-Marx S, Horne R, Deighton C, Kiely P, Mallen C, Raza K. 2019; Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study. BMJ Open. 9(3):e024361. 30 Siddle HJ, Bradley SH, Anderson AM, Mankia K, Emery P, Richards SH. 2023; Opportunities and challenges in early diagnosis of rheumatoid arthritis in general practice. Br J Gen Pract. 73(729):152–4. 31 2021. The state of musculoskeletal health 2021: arthritis and other musculoskeletal conditions in numbers.
RkJQdWJsaXNoZXIy MTk4NDMw